WuXi PharmaTech 3Q10 Above Jefferies & Company Estimate

WuXi PharmaTech WX reported 3Q10 EPS of $0.27 after adjusting for intangible amortization and transaction-related items, Jefferies & Company reports. “Revenue was $83.8M,” Jefferies & Company writes. “Our estimate was $0.19 on $80.2M. The company issued 2010 revenue guidance of $330M - $333M versus current consensus of $329M.” WuXi PharmaTech currently trades at $16.25.